Cargando…

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

BACKGROUND: KRAS codons 12 and 13 mutations predict resistance to anti-EGFR monoclonal antibodies (moAbs) in metastatic colorectal cancer. Also, BRAF V600E mutation has been associated with resistance. Additional KRAS mutations are described in CRC. METHODS: We investigated the role of KRAS codons 6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loupakis, F, Ruzzo, A, Cremolini, C, Vincenzi, B, Salvatore, L, Santini, D, Masi, G, Stasi, I, Canestrari, E, Rulli, E, Floriani, I, Bencardino, K, Galluccio, N, Catalano, V, Tonini, G, Magnani, M, Fontanini, G, Basolo, F, Falcone, A, Graziano, F
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Genetics and Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736831/ https://www.ncbi.nlm.nih.gov/pubmed/19603018 http://dx.doi.org/10.1038/sj.bjc.6605177

Ejemplares similares

Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
por: Cremolini, C, et al.
Publicado: (2010)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
por: Nakamura, Masato, et al.
Publicado: (2016)

Different oncological features of colorectal cancer codon-specific KRAS mutations: Not codon 13 but codon 12 have prognostic value
por: Ahn, Hong-Min, et al.
Publicado: (2023)

KRAS Codon 12 and 13 Mutations in Gastric Cancer in the Northeast Iran
por: Ayatollahi, Hossein, et al.
Publicado: (2018)

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2011)

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
por: Ali, Moiez, et al.
Publicado: (2017)

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
por: Jänne, P A, et al.
Publicado: (2015)

Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
por: Imamura, Yu, et al.
Publicado: (2014)

Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages
por: Li, Wenbin, et al.
Publicado: (2015)

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
por: van de Haar, Joris, et al.
Publicado: (2023)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer
por: Renaud, Stéphane, et al.
Publicado: (2016)

Do we need biopsies of metastases for colorectal cancer patients?
por: Floriani, I, et al.
Publicado: (2009)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
por: Naseem, Madiha, et al.
Publicado: (2021)

KRAS codon 12 mutations characterize a subset of de novo proliferating “metaplastic” Warthin tumors
por: Agaimy, Abbas, et al.
Publicado: (2023)

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial
por: Vincenzi, B, et al.
Publicado: (2006)

Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
por: Jones, Robert P, et al.
Publicado: (2017)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
por: Kim, Seung Tae, et al.
Publicado: (2015)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
por: von Einem, J. C., et al.
Publicado: (2014)

Analysis of KRAS Mutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing
por: Zinsky, Rica, et al.
Publicado: (2010)

Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study
por: Wangefjord, Sakarias, et al.
Publicado: (2013)

High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer
por: Korphaisarn, Krittiya, et al.
Publicado: (2019)

Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
por: Graziano, F, et al.
Publicado: (2008)

FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations
por: Amicarelli, Giulia, et al.
Publicado: (2007)

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007)

Codon Adaptation Index as a measure of dominating codon bias
por: Carbone, A, et al.
Publicado: (2002)

Single-Tubed Wild-Type Blocking Quantitative PCR Detection Assay for the Sensitive Detection of Codon 12 and 13 KRAS Mutations
por: Huang, Jun-Fu, et al.
Publicado: (2015)

BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients
por: Chen, Jing, et al.
Publicado: (2014)

Comprehensive Validation of Snapback Primer-Based Melting Curve Analysis to Detect Nucleotide Variation in the Codon 12 and 13 of KRAS Gene
por: Zhang, Qunfeng, et al.
Publicado: (2018)

Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis
por: Kwak, Min Seob, et al.
Publicado: (2017)

KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research
por: He, Kang, et al.
Publicado: (2020)

Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis
por: Yoshino, T., et al.
Publicado: (2022)

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
por: Masuishi, Toshiki, et al.
Publicado: (2020)

Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
por: Spindler, K-L G, et al.
Publicado: (2014)

Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity
por: IMPROTA, GIUSEPPINA, et al.
Publicado: (2013)

Identification of Codon 146 KRAS Variants in Isolated Epidermal Nevus and Multiple Lesions in Oculoectodermal Syndrome: Confirmation of the Phenotypic Continuum of Mosaic RASopathies
por: Beyens, Aude, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7ns46v4tgeuadibm5gb9tpcis5